Recruiting

Observational Study

Sponsor:

Dr. Daniel Cameron & Associates

Code:

NCT05312619

Conditions

COVID-19

Lyme Disease

COVID-19 Vaccine

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Cross sectional survey

Study Details

Brief summary:

A cross-sectional descriptive survey of the BOLD for individuals after having been ill with COVID-19 or have taken the COVID-19 vaccine will be compared with that of individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine. Individuals who have both been ill and taken the COVID-19 vaccine will be compared to identify any additive risk factors.

Conditions

COVID-19

Lyme Disease

COVID-19 Vaccine

Study ID

NCT05312619

Start date

Jul 7, 2021

Status verified date

Mar, 2022

Completion date

Nov 7, 2023

Anticipated

Primary completion date

Jul 7, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • ≥12 years old
  • a self-report of having been diagnosed with Lyme disease.

Exclusion Criteria:

  • There are no exclusion criteria.

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Interventions

Cross sectional survey

A cross-sectional descriptive survey of the Burden of Lyme disease for individual with a history of Lyme disease who contract COVID-19 or are vaccinated against COVID-19

Primary outcome measure

  • Burden of Illness using a General Symptom Questionnaire-30 questionnaire (GSQ-30) [ Time Frame: 7/21 to 7/23 ]

Central Contacts and Locations

Central contacts

Daniel Cameron, MD, MPH

9143251471dcameron@danielcameronmd.com

Locations

Daniel Cameron

Recruiting

Mount Kisco, New York, United States, 10549

Contacts

Daniel Cameron, MD, MPH

914-325-1471dcameron@danielcameronmd.com

More Information

Sponsor

Dr. Daniel Cameron & Associates

Last update posted

Apr 5, 2022

Last verified

Mar, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-20. This information was provided to ClinicalTrials.gov by Dr. Daniel Cameron & Associates on 2022-04-05.